Our analysis results showed that compared with the high expression group of S100A9, the patients in the low expression group of S100A9 had higher TMB (Figure 3B) and the scores of mismatch repair relevant signatures (Figure 3C), which to some extent supported the above analysis result that GBM patients in the low expression group of S100A9 had a better prognosis. The gene discussed is S100A9; the disease is glioblastoma.